Literature DB >> 16020742

Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling.

Olivia S Gardner1, Brian J Dewar, Lee M Graves.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are a subfamily of nuclear hormone receptors that function as ligand-activated transcription factors to regulate lipid metabolism and homeostasis. In addition to their ability to promote gene transcription in a PPAR-dependent manner, ligands for this receptor family have recently been shown to induce mitogen-activated protein kinase (MAPK) phosphorylation. It is noteworthy that the transcriptional changes induced by PPAR ligands can be separated into distinct PPAR- and MAPK-dependent signaling pathways, suggesting that MAPKs alone mediate some of the effects of PPAR agonists in a nongenomic manner. This review will highlight recent studies that elucidate the nongenomic mechanisms of PPAR ligand-induced MAPK phosphorylation. The potential relevance of MAPK signaling in PPAR biology is also discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16020742     DOI: 10.1124/mol.105.012260

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  34 in total

1.  Comparison of direct action of thiazolidinediones and glucocorticoids on renal podocytes: protection from injury and molecular effects.

Authors:  Shipra Agrawal; Adam J Guess; Rainer Benndorf; William E Smoyer
Journal:  Mol Pharmacol       Date:  2011-06-02       Impact factor: 4.436

2.  Hepatic inflammation and insulin resistance in pre-diabetes - further evidence for the beneficial actions of PPAR-gamma agonists and a role for SOCS-3 modulation.

Authors:  Prabal K Chatterjee
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

3.  Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism.

Authors:  Aleksandra Mieczkowska; Michel F Baslé; Daniel Chappard; Guillaume Mabilleau
Journal:  J Biol Chem       Date:  2012-05-16       Impact factor: 5.157

4.  Peroxisome proliferator-activated receptor-gamma activation suppresses HIV-1 replication in an animal model of encephalitis.

Authors:  Raghava Potula; Servio H Ramirez; Bryan Knipe; Jessica Leibhart; Kathy Schall; David Heilman; Brenda Morsey; Aaron Mercer; Anil Papugani; Huanyu Dou; Yuri Persidsky
Journal:  AIDS       Date:  2008-08-20       Impact factor: 4.177

5.  Thiazolidinediones are partial agonists for the glucocorticoid receptor.

Authors:  L Matthews; A Berry; M Tersigni; F D'Acquisto; A Ianaro; D Ray
Journal:  Endocrinology       Date:  2008-09-18       Impact factor: 4.736

6.  Molecular pathways: environmental estrogens activate nongenomic signaling to developmentally reprogram the epigenome.

Authors:  Rebecca Lee Yean Wong; Cheryl Lyn Walker
Journal:  Clin Cancer Res       Date:  2013-04-02       Impact factor: 12.531

7.  Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats.

Authors:  Sajay B Churi; Omar S Abdel-Aleem; Kiranjeet K Tumber; Heather Scuderi-Porter; Bradley K Taylor
Journal:  J Pain       Date:  2008-04-03       Impact factor: 5.820

8.  Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels.

Authors:  B Chopra; N T Georgopoulos; A Nicholl; J Hinley; M B Oleksiewicz; J Southgate
Journal:  Cell Prolif       Date:  2009-07-10       Impact factor: 6.831

9.  Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors.

Authors:  Miriam Melis; Giuliano Pillolla; Antonio Luchicchi; Anna Lisa Muntoni; Sevil Yasar; Steven R Goldberg; Marco Pistis
Journal:  J Neurosci       Date:  2008-12-17       Impact factor: 6.167

10.  Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists.

Authors:  Martin B Oleksiewicz; Jennifer Southgate; Lars Iversen; Frederikke L Egerod
Journal:  PPAR Res       Date:  2009-01-28       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.